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Objective: To identify the effect of decongestive lymphedema treatment on excess arm volume or patient-centered
outcomes in women presenting within either 12 months or a mean nine months of developing arm lymphedema
following breast cancer treatment.
Introduction: Lymphedema is a common consequence of breast cancer treatment requiring life-long treatment to
reduce symptoms and prevent complications. Currently, evidence to inform the optimal decongestive lymphedema
treatment package is lacking.
Inclusion criteria: The review included studies on women who received lymphedema treatment within either 12
months or a mean of nine months of developing unilateral breast cancer-related arm lymphedema. The intervention
was any decongestive lymphedema treatment delivered with the purpose of reducing arm lymphedema, compared
to another form of lymphedema treatment (whether self or practitioner-administered), placebo or no treatment. The
clinical outcome was excess arm volume; patient-centered outcomes were health-related quality of life, arm
heaviness, arm function, patient-perceived benefit and satisfaction with treatment. Experimental study designs
were eligible, including randomized and non-randomized controlled trials, quasi-experimental, prospective and
retrospective before and after studies were considered.
Methods: A three-step search strategy was utilized to find published and unpublished studies. The search identified
studies published from the inception of each database to July 6, 2016. Reference lists were scanned to identify further
eligible studies. Studies were critically appraised using appropriate standardized critical appraisal instruments from the
Joanna Briggs Institute. Details describing each study and treatment results regarding outcomes of interest
were extracted from papers included in the review using appropriate standardized data extraction tools from the
Joanna Briggs Institute. Due to heterogeneity in included studies, results for similar outcomemeasureswere not pooled
in statistical meta-analysis. A narrative and tabular format was used to synthesize results from identified and included
studies.
Results: Seven studies reporting results for outcomes of interest were critically appraised and included in the
review: five randomized controlled trials and two descriptive (uncontrolled) studies. Reported outcomes included
excess arm volume (five studies), health-related quality of life (three studies), arm heaviness (one study), arm function
(two studies) and patient-perceived benefit (two studies). There was some evidence that decongestive treatments
were effective for women presenting within either 12months or a mean of ninemonths of developing breast cancer-
related arm lymphedema, but the wide range of data prevented comparison of treatment findings which limited our
ability to answer the review questions.Correspondence: Eunice Jeffs, eunice.jeffs@kcl.ac.uk
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SYSTEMATIC REVIEW E. Jeffs et al.Conclusions: Weak evidence (grade B) for the impact of decongestive lymphedema treatment on women with
early lymphedema (i.e. less than 12 months duration of BCRL symptoms) did not allow any conclusions to be drawn
about the most effective treatment to be offered when these women first present for treatment. Findings provided
no justification to support change to current practice.
Future primary research needs to focus on the most effective treatment for women when they first present with
lymphedema symptoms, e.g. treatment provided within 12 months of developing symptoms. Studies should be
adequately powered and recruit women exclusively with less than 12 months duration of breast cancer-related
lymphedema symptoms, provide longer follow-up to monitor treatment effect over time, with comparable
treatment protocols, outcome measures and reporting methods.
Keywords breast cancer; decongestive lymphedema treatment (DLT); lymphedema
JBI Database System Rev Implement Rep 2018; 16(2):453–506.Introduction
L ymphedema is a common sequelae of breastcancer treatment, causing arm swelling in
around 20% of women following axillary node
dissection.1 For example, of the 54,833 cases of
female breast cancer diagnosed in the UK in
2014,2 it is likely that around 7000 of these women
had developed arm swelling. Breast cancer-related
lymphedema (BCRL) of the arm is a chronic tissue
swelling arising from damage to lymph nodes and
vessels, which may affect the ipsilateral arm and/or
trunk, and women are considered to be at increased
life-time risk of developing arm lymphedema follow-
ing breast cancer treatment.3-6 Breast cancer-related
lymphedema has significant physical, functional and
psychological impact on the individual woman, with
challenges for work, social and leisure activities, and
potential financial implications.5-10
Lymphedema is a progressive condition, moving
from an acute phase of subclinical edema (Interna-
tional Society of Lymphology/ISL grade 0), through
mild or transient swelling, to chronic swelling with
irreversible changes (ISL stage III).11,12 There is no
agreement regarding the diagnostic threshold for
lymphedema. At stage I, lymphedema may reduce
with limb elevation, although by stage II tissue
changes are occurring and pitting edema is present
which no longer reduces with elevation alone; stage
IIa indicates that excess fat and fibrotic changes are
becoming established in the limb and pitting of
edemamay no longer be achieved; at stage III, pitting
may be absent due to skin thickening, fatty deposits
and increased fibrosis leading to characteristic
changes of elephantiasis.12 The rate of progression
is unknown but will vary between individuals, how-
ever chronic changes are likely to occur within 12JBI Database of Systematic Reviews and Implementation Reports
WOLTERS KLUWER HEALTHmonths of the onset of swelling.13 What is known is
that without effective treatment, significant tissue
changes can occur over time resulting in chronic,
more severe lymphedema with tissue fibrosis which
is less responsive to treatment and associated with
increased morbidity.11,14 There is some evidence
that the damage cannot be reversed once advanced
lymphedema is established.15
The goal of lymphedema treatment is deconges-
tion of the arm, that is, removal of excess lymph and
associated tissue changes, to return the arm to a
latent (hidden) phase of swelling. The improved
swelling can then be managed by the individual with
little personal or specialist input,12,14 although
BCRL requires life-long self-management to reduce
and control symptoms, prevent development of com-
plications, and prevent recurrence of symptoms once
the latent phase is achieved.14,16
Treatment of lymphedema aims to decongest the
swollen limb and generally combines a form of
compression (whether bandaging, hosiery or pneu-
matic compression therapy) with different forms of
exercise (resistive, sequential; land or water-based),
lymphatic massage, skin care and advice, and sup-
port for the patient;12,14,16 other treatments such as
laser therapy have been used, and microsurgery and
liposuction have increased in recent years.12 The
internationally accepted current recommended best
practice for lymphedema treatment is a two-phase
decongestive lymphedema treatment (DLT), also
commonly known as complex decongestive therapy
(CDT).12,14,16,17 The first ‘‘intensive treatment’’
phase aims to decongest the swollen arm through
two or more weeks of daily therapist-delivered treat-
ment including multi-layer compression bandaging
andmanual lymph drainage (MLD). This is followedCOPYRIGHT  2018 THE AUTHORS. PUBLISHED BY 454
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with compression usually in the form of hosiery.14
There is some evidence of the effectiveness of DLT to
reduce lymphedema,17-20 although studies to date
have largely been underpowered, varied in their
treatment protocol and assessment methods, and
lack sufficient duration of follow-up (i.e. at least
six months) to demonstrate any sustained treatment
effect for this chronic condition.17,21,22
Assessment and monitoring of lymphedema gen-
erally include some objective measurement of size,
which may be combined with self-assessment of
health-related quality of life and symptoms, such
as arm heaviness and arm function.14,23 Excess
arm volume is the difference between the volume
of swollen and non-swollen arms, and takes into
account any changes to the whole body (such as body
weight) bymonitoring impact on the unaffected arm;
change may be reported as an increase or decrease in
excess arm volume.14 However, there is no agree-
ment regarding the preferred methods for reporting
changes following lymphedema treatment.
A search of the Cochrane Database of Systematic
Reviews and Medline database using the keywords
‘‘lymphedema’’, ‘‘breast cancer’’ and ‘‘review’’ was
undertaken to establish the existence of any published
systematic review and/or protocols for review regard-
ing the population of interest. In the past six years,
published systematic reviews have addressed the
effectiveness of lymphedema treatment programs
for women with BCRL17-20,22,24-27 and individual
treatment modalities; for example, low level laser
therapy (LLLT),28-30 intermittent pneumatic com-
pression therapy (IPCT),20,31,32 and manual lymph
drainage (MLD).33,34 However, no systematic review
or protocol was found, and although Shah et al.19
reviewed evidence on the effectiveness of early detec-
tion and intervention to reduce the incidence of BCRL
they did not focus on the effectiveness of treatment for
lymphedema once symptoms are established. There is
a need to specifically address the treatment of early
lymphedema, where the skin and tissues are most
likely to be responsive to treatment. For the purpose
of this review, treatment is any intervention applied
with the intent to decongest the swollen arm and early
lymphedema is considered to be within 12 months of
developing symptoms.35,36
This systematic review provides lymphedema
practitioners, womenwith BCRL, and other decision
makers with the first synthesis of available evidenceJBI Database of Systematic Reviews and Implementation Reports
WOLTERS KLUWER HEALTHfor the effect of decongestive lymphedema treatment
on excess arm volume and/or patient-centered out-
comes when provided within either 12 months or a
mean of nine months of symptoms developing. To
guide the completion of this systematic review, a
research protocol was designed and published in the
Joanna Briggs Institute Database of Systematic
Reviews and Implementation Reports.37
Review question
The objective of the review was to identify the effect
of decongestive lymphedema treatment on excess
arm volume and patient-centered outcomes for
women presenting within either 12 months or a
mean of nine months of developing a swollen arm
due to breast cancer-related lymphedema (BCRL).
The specific review questions to be addressed were:
, INWhat is the most effective combination of treat-
ment elements for these women? What is the optimal duration of treatment?
Inclusion criteria
Participants
This review considered studies that included women
with unilateral BCRLof the armwho received lymph-
edema treatmentwithin 12months of developing arm
swelling. Although progression of lymphedema will
vary between women, it is reasonable to assume that
sufficient skin and tissue changes will have occurred
by 12months to affect the outcome of treatment. The
original intention was to exclude from this review
women withmore than 12months duration of symp-
toms. However, due to a lack of studies where the
durationofBCRLsymptomswas less than12months,
a decision was made to also consider studies if the
average (mean)durationof swellingwas less thannine
months. This time frame was considered likely to
maximize the inclusion of studies with a large pro-
portion of women with BCRL of less than 12 months
duration but limit the number ofwomenwith chronic
lymphedema (i.e. more than one year duration). Stud-
ies were also considered if outcomes were separately
reported for a subgroup of women with less than
12months duration; outcomes for women with more
than 12 months duration were excluded.
Studies which reported participants with other
forms of lymphedema (e.g. leg lymphedema, breast/
truncal edema) were only included if data were sepa-
rately reported for armBCRL. Studieswhich included
bilateral lymphedema or individuals defined as ‘‘atCOPYRIGHT  2018 THE AUTHORS. PUBLISHED BY 455
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which included women with BCRL receiving concur-
rent cancer treatment (whether curative or palliative),
with the exception of hormone therapy, were
excluded as cancer treatment such as chemotherapy
or radiotherapy could exacerbate BCRL through
inflammation or increased fluid load.38 Men with
BCRLwere excluded from the review as the incidence
of male breast cancer is less than 1%.2
Interventions
Studies were considered that evaluated any conserva-
tive non-drug treatment where the goal was to decon-
gest the arm, that is, reduce lymphedema, whether
delivered by lymphedema therapist or patient self-
management. The review was as inclusive as possible
to capture all forms of decongestive treatment. The
studies included, but were not limited to, the combi-
nation of treatments known as decongestive lymph-
edema treatment or DLT, complex/complete
decongestive treatment or CDT; compression ther-
apy,whetherbandaging, garmentsorpneumatic com-
pression pump; exercise, such as resistance training or
hydrotherapy; low level laser therapy; manual lymph
drainage or lymphatic massage.
Studies evaluating surgical or drug therapy inter-
ventions, treatment of progressive lymphedema due
to uncontrolled active cancer, safety assessment of
treatment, interventions used without the intention
of lymphedema decongestion, evaluation of a single
session of treatment (such as compression bandaging
or hosiery, manual lymph drainage or exercise),
interventions to reduce the risk of developing BCRL,
or assessment techniques were excluded.
Comparators
Relevant experimental studies could compare out-
comes with another form of lymphedema treatment
(whether patient or lymphedema therapist adminis-
tered), placebo or no treatment.
Outcomes
The review considered studies that included the fol-
lowing clinical or patient-centered outcome measures:
JBIThe clinical outcome of interest was excess arm
volume. Studies were sought which expressed
the outcome as a relative change in excess arm
volume (that is, compared to the non-swollen arm),
whether measured by water displacement, perom-
etry or circumference measurements to calculateDatabase of Systematic Reviews and Implementation Reports
WOLTERS KLUWER HEALTH, INarm volume. In the absence of relative change in
excess arm volume, the intention was to consider
the relative change in tissue fluid measured by
bioimpedance or tissue dielectric constant. The patient-centered outcomes of interest were
health-related quality of life, sensation of heavi-
ness in the swollen arm, arm function, patient-
perceived benefit or satisfaction with treatment.
Studies which used an appropriate validated
assessment tool or, in the absence of a validated
tool, visual analog scales were included.
Studies which did not report on either the relative
change to arm size/tissue fluid volume, psychosocial
or patient self-report outcome measure, or patient
value of treatment were excluded.
Types of studies
The review included experimental study designs:
randomized controlled trials, non-randomized con-
trolled trials and quasi-experimental studies. It also
considered descriptive (uncontrolled) studies includ-
ing before and after studies, whether prospective
or retrospective.
Methods
Search strategy
Studies were identified using a three-step search strat-
egy. Firstly, a limited search of MEDLINE, Embase
and CINAHL was undertaken to identify key words
and index terms used in the title and abstract. Further
scoping searches were used to identify the search terms
and refine them for maximum sensitivity and specific-
ity, to identify appropriate databases to ensure a thor-
ough search of the relevant literature, and to ensure
comparable search strategies across each chosen data-
base. Database search terms were limited to variants
of ‘‘breast cancer’’ and ‘‘lymphedema’’ in title and
abstract fields, and reviews of the lymphedema liter-
ature, as attempts to refine the search by including
additional treatment-relatedkeywords led to the lossof
potentially relevant papers. Secondly, a systematic
search across all relevant electronic bibliographic data-
bases using all identified variants of key words and
index terms was undertaken to identify published and
unpublished quantitative studies; the final search strat-
egy (Appendix I) was deliberately left open with the
expectation that eligibility criteria would be applied at
the screening stage to a large number of references.
Thirdly, reference lists and bibliographies of retrieved
articles were reviewed and four specialist lymphologyCOPYRIGHT  2018 THE AUTHORS. PUBLISHED BY 456
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located through other search strategies.
Using the search strategy (Appendix I), the follow-
ing databaseswere searchedwithout date restrictions,
on July 6, 2016 (except where specified), to identify
studies published in the commercial literature (i.e.
black literature): Allied and Contemporary Medicine
(AMED), Biomed Central (search completed to July
1, 2015 as original search strategy could not be
replicated in July 2016 due to changes to the database
search function), BIOSIS (records were only available
for the period 1969 to 2008 due to subscription
limitations), British Nursing Index, CINAHL,
Cochrane Library (Wiley Online Library), Embase,
HMIC, MEDLINE, Physiotherapy Evidence Data-
base (PEDro), PsycARTICLES, PsycINFO, PubMed,
Scopus, Turning Research into Practice (TRIP)
(search completed to July 1, 2015 as records obtained
in July 2016 could no longer be downloaded to
EndNote database without additional subscription),
Web of Science and WorldCat. Preliminary searches
ofMEDLINE and PubMed identifiedmany duplicate
references but each produced some references which
were not included by the other database, so both
databases were included in the final search.
The following databases were searched on July 4,
2016 to identify studies conducted but not published
in the commercial literature (i.e. gray literature):
ClinicalTrials.gov (USA), Controlled Trials Register
(ISRCTN), Grey Literature Report (http://www.greylit.
org/ and www.opengrey.eu), International Clinical
Trials Registry Platform (ICTRP), WorldCat Article-
First (OCLC), WorldCat Dissertations, WorldCat
PapersFirst and WorldCat ProceedingsFirst.
The following databases were included in the
review protocol search strategy but, following pre-
liminary searches,were excluded from the final search
strategy for the reasons specified: PROSPERO, Cen-
tre for Reviews and Dissemination reports only pro-
tocols for systematic reviews so not a source for
primary research; DARE database is no longer main-
tained, but DARE records are included within the
Cochrane Library; Clinical Trials Registers/UK Clin-
ical Research Network (UKCRN) is now the Central
PortfolioManagement Systemwhich draws from two
databases in the search strategy, i.e. ClinicalTrials.
gov, ISRCTN; Conference Proceedings Citations
Index (Web of Science) was included in the search
ofWebof ScienceCoreCollection; EvidenceNHSUK
(NICE) searches databases included in the searchJBI Database of Systematic Reviews and Implementation Reports
WOLTERS KLUWER HEALTHstrategy, i.e. AMED, British Nursing Index,
CINAHL, Embase, HMIC, MEDLINE and Psy-
cINFO; National Guideline Clearing House (USA)
reports summaries of evidence and searches databases
included in the search strategy, i.e. PubMed, Embase,
CINAHL, the Cochrane Library, PsycINFO.
Online hand-searching of the titles and abstracts
of all available editions of four lymphedema-specific
journals took place on July 6, 2016: European
Journal of Lymphology, Journal of Lymphoedema,
Journal of Phlebology and Lymphology and Lym-
phology. In addition, the reference lists of published
systematic reviews17-22,24,27-34,39-53 identified in the
search were examined for additional references.
The review considered English and non-English
language publications which provided an English
language abstract. The development of current
lymphedema treatment originated in continental
Europe so no language restrictions were applied to
the searches. The search of relevant foreign language
full text papers to confirm eligibility for inclusion
was conductedwith the help of colleagues and online
translation tools. As there were no eligible non-
English language publications, it was not necessary
to obtain a full translation of any paper.
The results obtained from each database search
were electronically imported into EndNote X7 cita-
tion manager (Thomson Reuters, USA) and com-
bined into a single library. Duplicate records were
recorded and removed prior to screening.
All studies identified during the database searchwere
assessed against the review eligibility criteria based on
the information provided in the title and abstract.
Studies identified from searching the reference lists were
assessed for relevance based on the study title. A full
report was retrieved and assessed for relevance for all
studies which met the inclusion criteria or had insuffi-
cient detail in the abstract to determine eligibility.
Assessment of methodological quality
The methodological quality of studies selected for
inclusion was independently assessed by two
reviewers (EJ and DB) using standardized critical
appraisal instruments from the Joanna Briggs Insti-
tute System for the UnifiedManagement, Assessment
and Review of Information (JBI SUMARI), namely
the Randomized Control/Pseudo-randomized Trial
tool and Descriptive/Case Series Study tool.54
Adecisionwasmadenot to exclude relevantpapers
on grounds of methodological quality, but to reportCOPYRIGHT  2018 THE AUTHORS. PUBLISHED BY 457
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through discussion any differences of opinion that
arose regardingmethodological quality; the input of a
third independent reviewer (ER) was not required.
Data extraction
Details describing each study and results for the
outcomes of interest were extracted from included
papers using the standardized data extraction tool
from JBI SUMARI.54 In addition to extraction of
results for outcomes relevant to the review objectives
and questions, extracted information included
details about the interventions, populations and
method of the included studies. Where studies
reported outcomes for a subgroup of women with
BCRL duration of less than 12 months or a mean of
nine months, data was not extracted for those
women with either more than 12 months or a mean
of nine months BCRL duration.Records identified through 
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Outcomes were expressed as continuous data, with
means and standard deviation extracted from the
included papers, where available, and analyzed. Due
to wide study heterogeneity, the results for similar
outcomes were not pooled in statistical meta-analy-
sis. Instead, a narrative and tabular format have been
used to display the results of this review.
Two subgroup comparisons were planned for: i)
previous lymphedema treatment (yes or no), and ii)
severity of swelling at baseline, whether mild or
moderate-severe, where reported and as defined
within the study. However, sub-group analysis could
not be performed due to lack of data.
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the search for commercially published and gray
literature. After removal of duplicate records and
screening by title and abstract, 187 records remained
for full text review, of which two papers55,56 could
not be obtained via interlibrary loan. Authors of six
conference abstracts were contacted to clarify eligi-
bility criteria although none responded; 23 records
of conference presentations could not be screened as
they lacked an abstract, and four further records of
conference presentations were excluded as they
lacked corresponding author details to clarify miss-
ing data relating to eligibility criteria. Twenty-one
study protocols were excluded, primarily because
the study samples were not the population of interest
for this review. Information about the duration of
lymphedema symptoms was lacking in 66 published
papers, of which 47 were published within the pre-
vious 10 years, so corresponding authors were con-
tacted for to clarify whether they could report
outcomes for either the study sample or a subgroupTable 1: Results of critical appraisal for appraising r
Citation
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allocation
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blinded
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Allocator
blinded
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ITT
analysis
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blinded
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201582
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BCRL duration. Responses were received regarding
24 papers, of which 21 papers were excluded as
duration of BCRLwas unknown57-66 or greater than
12months/a mean of nine months,67-74,76-78 and
three papers35,36,75 met the inclusion criteria.
Appendix II lists the 180 studies excluded following
full text examination and reasons for their exclusion.
Seven studies35,36,75,79-82 were critically appraised
and included in the review regardless of their
methodological limitations.
Methodological quality
The results of the quality assessment using the JBI
SUMARI appraisal tools for randomized controlled/
pseudo-randomized trials and for descriptive
(uncontrolled) studies are presented in Tables 1
and 2. Two35,36 of the five controlled studies and
one descriptive study79 may be described as moder-
ate to high quality, whereas the other studies75,80-82
were rated as having poor methodological quality.andomized controlled / pseudo-randomized trials
Q6
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comparable
Q7
Treated
equally
Q8
Same
outcomes
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Reliably
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analysis Total
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There were significant areas of bias in all study
methods described.
Five studies were randomized controlled trials,
however only two35,36 provided descriptions of the
computer-generated randomization method demon-
strating true random allocation with allocation con-
cealed from allocator, whereas three80-82 merely
stated that participants were randomized.
In only two studies35,36 were the assessors blinded
to treatment allocation; the other three studies80-82
did not report whether the assessor was blinded (Q5,
Table 3), meaning that risk of detection bias is
unknown. Only one study81 used an intervention
that could be blinded to both participants and asses-
sors, although the method of providing sham laser
was not reported. The other four studies35,36,80,82
could not disguise the study interventions so partic-
ipants were not blind to treatment allocation.
Three studies36,80,81 reported comparable inter-
vention and control groups at entry to the study,
although sample sizes were small, ranging from four
to 57 participants in each study, which affects the
precision of estimates and increases the possibility of
failure to detect an effect that is present (type II
error).
One study,80 with no attrition, reported outcomes
on an intention to treat basis. The other four stud-
ies35,36,81,82 reported reasons for attrition: two
studies36,81 reported outcomes for only those who
completed the study; one study82 reported data
without citing the number of participants repre-
sented in the data; one study35 reported participant
data available for each reported time-point.
Outcomes were measured in the same way for
both intervention groups in all five controlled stud-
ies.35,36,80-82 As already noted, two of these stud-
ies80,81 did not measure in a reliable way all reported
outcomes of interest so these data were not included
in this review.
Descriptive studies
One uncontrolled retrospective case review study79
had low risk of bias. Possible bias in the other
prospective study75 included insufficient detail to
ensure reproducibility of reported outcomemeasure-
ments; no follow-up of study outcomes following
the immediate post-intervention period; and self-
reported symptoms monitored using a tool that
had not been validated.JBI Database of Systematic Reviews and Implementation Reports
WOLTERS KLUWER HEALTHCharacteristics of included studies
The key characteristics of the seven included stud-
ies35,36,75,79-82 are described below and, where
appropriate, separately treated as controlled and
descriptive/uncontrolled studies. Appendix III pro-
vides a summary of the characteristics by study.
Types of studies
Five studies were randomized controlled trials:
two35,36 provided descriptions of the computer-gen-
erated randomization method, whereas three80-82
merely stated that participants were randomized.
The final two papers were uncontrolled studies:
one prospective before and after study75 and one
retrospective case review.79
Participants and setting
No study specifically addressed the population of
interest, although three studies35,36,75 reported one
or more outcomes for a subgroup (n¼132) of
women with BCRL duration 1 year from a total
study sample of 282 women. Two studies80,81
(n¼48) reported outcomes for the total study sam-
ple of women with a mean duration of no more than
9 months (pooled mean 5.08 months; pooled SD
11.64), and two studies79,82 reported outcomes for a
subgroup (one of the intervention groups) with a
mean duration of no more than 9 months (mean
8.56.6 and 8.37.2 months respectively, n¼57)
from a total study sample of 108 women. Five
studies35,79-82 (n¼150) reported mean age with a
pooled estimate of 54.709.88 years; two stud-
ies36,75 reported age only for the total population,
including women with >12 months duration BCRL.
Only two studies each recruited more than 50
women with less than 12 months duration of BCRL
symptoms35,75 (n¼58 and 60). The number of par-
ticipants with either less than 12 months BCRL
duration or group mean 9 months duration of
symptoms ranged from 8 to 40 in the other five
studies.36,79-82
Breast cancer-related lymphedema was defined in
the five controlled studies by arm size difference, but
not in either descriptive study,75,79 using various
diagnostic criteria recognized by the lymphedema
community:83 two studies35,81 defined lymphedema
as >10% excess arm volume and one study82 as
>20% excess arm volume; one study36 defined
BCRL as >150 ml difference between arms; one
study80 described >2 cm circumference differenceCOPYRIGHT  2018 THE AUTHORS. PUBLISHED BY 460
, INC. ON BEHALF OF THE JOANNA BRIGGS INSTITUTE.
SYSTEMATIC REVIEW E. Jeffs et al.between arms. Four studies categorized severity of
swelling at baseline, either according to the Interna-
tional Society of Lymphology staging,12,82 or rela-
tive (%) excess arm volume:35,36,79 Dayes et al.35
categorized severity as 10% to <20%, 20% to
<30%, and 30% excess arm volume, McNeely
et al.36 categorized severity as mild (<15% excess
arm volume), moderate (16–37%), or severe
(>37%), and Hwang et al.79 stratified severity as
<20% or 20% excess arm volume. Two stud-
ies75,82 explicitly stated that participants had not
received any treatment for BCRL prior to the inter-
vention, whereas the other five studies35,36,79-81
reported neither the number of women who had
previously received treatment nor the type of prior
treatment received.
Six studies35,36,75,79-81 were performed in Lymph-
edema Units or Rehabilitation Departments withinTable 3: Interventions in included studies
Study/citation Components of intervention
Duration and
frequency of
intervention
Complex decongestive treatment (CDT/CDPT/DLT)
Dayes et al.
201335,a
Intensive phase: MLD and short
stretch compression bandaging
(Vodder or Foldi method);
advice re skin care, exercise,
and maintenance of healthy
body weight.
Followed by maintenance phase:
elastic compression garments;
exercise, skin care, maintenance
of healthy body weight.
5 per week f
weeks (20 sess
Subsequent ma
nance treatmen
daily self-care
Gradalski et al.
201582,b
Multi-layer compression ban-
daging and Vodder II method
MLD, exercise and deep dia-
phragmatic breathing.
Followed by maintenance phase:
exercise, compression garment,
arm and skin care.
5 per week f
weeks (10 sess
Followed by 6
daily self-care.
Haghighat
et al. 201375,a,c
CDT phase I: Vodder method
MLD; multi-layer short-stretch
bandages; remedial exercise (not
specified); skin care.
5 per week f
weeks (10–15
sions).
Hwang et al.
201379,b,d
CDT phase I: 1 hour MLD,
multi-layer low stretch compres-
sion bandaging, remedial exer-
cises, skin care.
CDT phase II: compression gar-
ments daytime, self-bandage
night-time; self-MLD/self-mas-
sage; exercise; skin care.
5 per week f
weeks (10 sess
Then daily self
ment plus 3 tim
week night-tim
bandaging.
JBI Database of Systematic Reviews and Implementation Reports
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established health care systems; one study82 did
not describe the setting. Two studies35,36 were con-
ducted in Canada, two75,81 in Iran, two79,80 in
Korea, and one82 in Poland.
Interventions and comparators
There was heterogeneity of treatment method and
protocols. A summary of the interventions and pro-
tocols tested in the studies is presented in Table 3,
with more detail provided in appendices III and IV.
Only two studies36,82 provided sufficient detail to
replicate the method of intervention; the other five
studies35,75,79-81 require the reader to make assump-
tions regarding aspects of the treatment provided.
Four studies35,36,75,82 specified the lymphology
school where the therapists had trained. Two stud-
ies79,80 did not specify the method of MLD used.Comparator
Outcomes
measured
Measurement
method
or 4
ions).
inte-
t with
Compression ther-
apy: daily self
treatment, as per
maintenance
phase, see below
1. EAV
2. HRQOL
3. Limb
function
1. Manual circum-
ference measure-
ment
2. Short Form
Health Survey
(SF-36)
3. Disabilities of
the Arm Shoulder
and Hand (DASH)
questionnaire
or 2
ions).
months
Compression ban-
daging 5 per
week for 2 weeks
(10 sessions), fol-
lowed by 6 months
maintenance phase
of daily self-care,
see below.
1. EAV
2. HRQOL
3. Patient-
perceived
treatment
benefit
1. Manual circum-
ference measure-
ment
2. non-validated
lymphedema ques-
tionnaire
3. VAS: desire to
continue treatment
or 2–3
ses-
None 1. EAV
2. Symptom
of arm
heaviness
1. Water displace-
ment
2. VAS
or 2
ions).
-treat-
es per
e self-
None 1. EAV 1. Perometry
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Table 3. (Continued)
Study/citation Components of intervention
Duration and
frequency of
intervention Comparator
Outcomes
measured
Measurement
method
Kim et al.
201080,b
Termed ‘Complex Decongestive
Physiotherapy (CDPT)’
Intensive phase: MLD,
compression therapy, exercise,
breathing exercises.
Maintenance phase:
self-CDPT
5 per week for 2
weeks (10 sessions).
Then 6 weeks self-
administered CDPT.
Complex Decon-
gestive Therapy
plus Active Resis-
tive Exercise
(CDPTþARE), see
below
1. HRQOL 1. SF-36
Complex decongestive physiotherapy (CDPT) and active resistive exercise (ARE)
Kim et al.
201080,b
Intensive phase: MLD, compres-
sion bandage, exercises and
breathing exercises, plus Active
Resistive Exercise (ARE) pro-
gram using 0.5kg dumbbell.
Maintenance phase: self-
CDPTþARE using 1kg dumb-
bell (if tolerated), wearing
hosiery.
5 per week for 2
weeks (10 sessions).
Then 6 weeks self-
administered
CDPTþARE.
CDPT, see above 1. HRQOL 1. SF-36
Compression bandaging (CB) and manual lymph drainage (MLD)
McNeely et al.
200436,a
Short stretch bandages plus 45
minutes daily Vodder method
MLD. Education re arm care
and skin care.
5 per week for 4
weeks (20 sessions)
CB 5 per week
for 4 weeks (20
sessions), see
below
1. EAV 1. Water displace-
ment & manual
circumference
measurement
Compression bandaging (CB)
McNeely et al.
200436,a
Short stretch bandages.
Education re arm care
and skin care.
5 per week for 4
weeks (20 sessions)
CBþMLD 5 per
week for 4 weeks
(20 sessions), see
above
1. EAV 1. Water
displacement &
manual
circumference
measurement
Compression therapy
Dayes et al.
201335,a
Elastic compression garments,
advice re skin care, exercise and
maintenance of healthy body
weight.
Daily self-care with
compression garments
worn 12 hours per
day
CDT, 5 per
week for 4 weeks
(20 sessions). Sub-
sequent mainte-
nance treatment
with daily self-
care, see above
1. EAV
2. HRQOL
3. Limb
function
1. Manual
circumference
measurement
2. SF-36
3. DASH
questionnaire
Low level laser therapy (LLLT)
Kaviani et al.
200681,b
Laser diode (product specified),
output power 10 Watts at
890nm wavelength. Treatment
to five points in axilla at 1 cm
distance from skin, energy den-
sity 1.5J/cm2
3x per week for 3
weeks, then 8 week
break, then 3x per
week for 3 more
weeks. (18 sessions).
Sham irradiation
as per LLLT, total
18 sessions. Dou-
ble-blinded condi-
tions for sham
laser not specified.
1. Symptom
of arm
heaviness
2. Limb
function
3. Patient-
perceived
treatment
benefit
1. VAS
2. Goniometry:
range of move-
ment
3. VAS: desire to
continue treatment
EAV, excess arm volume; HRQOL, health-related quality of life; MLD, manual lymph drainage; VAS, visual analogue scale.
aSubgroup with BCRL duration <12 months.
bMean duration 9 months.
cProspective before and after (uncontrolled) study.
dRetrospective case review (uncontrolled) study.
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Complex decongestive treatment utilizes thera-
pist-delivered multi-layer compression bandaging
and MLD in the first/intensive phase of treatment,
followed by a maintenance phase of self-treatment
with compression hosiery in an effort to maintain the
long-term benefits of CDT.12
Five studies addressed the benefit of CDT: three
controlled studies35,80,82 each utilized a different
CDT protocol and comparator, and two uncon-
trolled studies75,79 also varied the protocol used.
Dayes et al.35 compared three weeks of phase 1
CDT with self-treatment, phase 2 CDT, with both
groups carrying out self-treatment for the remainder
of the study protocol; this study provided the only
comparison of intensive therapist treatment versus
patient self-treatment to decongest the arm. Gradal-
ski et al.82 compared twoweeks of phase 1 CDTwith
compression bandaging alone, followed by six
months of daily self-treatment (phase 2 CDT) for
both groups with flat-knit hosiery and continuation
of the exercise program and skin care. Kim et al.80
also utilized CDT although, as the focus of the study
was to determine the effect of adding active resistive
exercise to CDT, this study is reported below under
the heading of exercise.
Haghighat et al.75 prospectively reviewed the
effect of 10–15 sessions of phase 1 CDT over a
two-three week period; the protocol did not
include a period of phase 2 CDT. Hwang et al.79
conducted a retrospective review of patients who
received two weeks phase 1 CDT followed by
24 months of self-treatment (phase 2 CDT) with
compression hosiery, self-MLD, remedial exercises
and skin care, plus night-time self-bandaging three
times per week.
Compression bandaging and manual lymph
drainage (MLD)
One controlled study36 sought to ascertain
whether four weeks treatment with multi-layer com-
pression bandaging alone was sufficient to effect a
reduction in lymphedema or whether the additional
cost of therapist-providedMLD could be justified by
enhanced treatment outcomes. The study protocol
did not include a post intervention self-treatment or
maintenance phase.
Exercise
Exercise is considered a standard part of CDT,
both during the intensive therapist phase and theJBI Database of Systematic Reviews and Implementation Reports
WOLTERS KLUWER HEALTHsubsequent self-treatment maintenance phase. Five
studies35,75,79,80,82 reported exercise as part of the
study protocol, however, only one controlled study80
specifically examined the therapeutic role of exercise
to decongest the swollen arm. Kim et al.80 compared
CDT plus active resistive exercise with CDT alone,
with both intervention groups receiving two weeks
identical CDT comprising application of daily com-
pression bandages andMLD, and self-treatment with
daily remedial exercises and breathing exercises; this
was followed by a maintenance phase of six weeks
self-CDT. The CDT plus active resistive exercise
group undertook an additional daily 15minutes resis-
tive exercise throughout the two weeks CDT and six
weeks self-CDT.
One controlled study82 reported that an identical
unspecified exercise regime was carried out by both
groups, and another controlled study35 reported that
exercise was carried out by both groups but did not
specify the regime or whether both groups under-
took the same exercise regime. The two uncontrolled
studies75,79 included unspecified exercises as part of
the CDT regime.
Low level laser therapy
The treatment of lymphedemawith low level laser
therapy is thought to have a multi-factorial effect to
increase lymph flow and thereby reduce tissue fluid
and proteins.84 One study81 compared the effect of
light therapy (890nm wavelength) to placebo, that
is, sham laser. Both groups received three times
weekly treatment for three weeks (18 sessions);
the intervention group received one Joule energy
to each of five points in the axilla of the affected
arm, whereas the sham laser group did not receive
any laser energy. A further three weeks (18 sessions)
of active treatment or sham laser took place after an
eight week rest period. No concurrent treatment was
reported for either group.
Outcomes
A summary of the outcomes assessed in the studies
is presented in Table 4. Only one study36 reported
training the assessors. Of the three corres-
ponding authors35,36,75 who were contacted for
clarification of information specific to outcomes
for women with <12 months duration of BCRL,
one author35 supplied all the requested data,
one75 supplied some of the requested data, and
the other36 reported the data were no longer avail-
able to them.COPYRIGHT  2018 THE AUTHORS. PUBLISHED BY 463
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Table 4: Outcomes measured in included studies
Study/citation Domain Outcomes measured Approach
Haghighat et al. 201375
McNeely et al. 200436
Change in excess
arm volume
Excess arm volume Water displacement
Hwang et al. 201379 Perometer
Dayes et al. 201335
Gradalski et al. 201582
McNeely et al. 200436
Manual circumference measurement
Dayes et al. 201335
Kim et al. 201080
Health-related
quality of life
Health-related quality of
life
Short Form Health Survey (SF-36)
Gradalski et al. 201582 Health-related quality of
life
Lymphedema Questionnaire
(non-validated)
Haghighat et al. 201375
Kaviani et al. 200681
Symptom of
heaviness
Sensation of heaviness in
affected arm
Visual Analogue Scale (VAS),
subjective reporting by patient
Kaviani et al. 200681 Limb function Range of movement VAS, subjective reporting by patient
Dayes et al. 201335 Disabilities of the arm,
shoulder and hand
Disabilities of the Arm, Shoulder and
Hand (DASH) Questionnaire
Gradalski et al. 201582
Kaviani et al. 200681
Patient-perceived
benefit or satisfac-
tion with treatment
Desire to continue
treatment
VAS, subjective reporting by patient
SYSTEMATIC REVIEW E. Jeffs et al.The most common outcome measure used
to evaluate CDT was excess arm volume:
five35,36,75,79,82 of the seven studies reported changes
in excess arm volume. Three standard measurement
methods were used to calculate volume: water dis-
placement;36,75 Perometry,79 an opto-electronic mea-
surement machine; and manual circumference
measurements,35,36,82 using the formula for a trun-
cated cone to calculate arm volume. Studies23,85,86
have shown these three measurement methods to be
equally valid, producing comparable but not inter-
changeable limb volume data. Volume changes were
variously reported in terms of pre and post interven-
tion excess arm volume82 pre and post intervention
percentage excess arm volume,35,79 post intervention
percentage reduction in excess arm volume,35,36,75
and post intervention relative change in excess arm
volume82 using the formulaproposedbyAncukiewicz
et al.;87 McNeely et al.36 reported outcomes for the
population of interest only in graph format. Relative
change, whether reported as percentage reduction in
excess arm volume compared to baseline23 or using
the formula for ratio of ratios proposed by Ancukie-
wicz et al.,87 takes into account variations within the
individual and between different women such as
the impact of bodymass on arm size. The arm volume
data reported by the two other studies80,81 were
excluded from the review as one81 calculated armJBI Database of Systematic Reviews and Implementation Reports
WOLTERS KLUWER HEALTHvolume using sum of circumferences, a method not
included in the review, and the other80 reported only
the volume of the affected arm; absolute volume does
not take into account the contralateral (unaffected)
armvolumeor changes that occur in both arms.None
of the studies35,36,75,79-82 measured bioimpedance
spectroscopy or tissue dielectric constant.
Health-related quality of life was reported in
two35,80 of the seven studies using the 36-item Short
Form Health Survey (SF-36; RAND, USA). The SF-
3688,89 is a set of eight self-reported quality of life
measures and has been widely used to assess the
impact of a health intervention on different compo-
nents of an individual’s health; summary scores are
used to derive physical andmental health component
scores, ranging from 0 to 100, with a higher score
indicating better overall function. It should be noted
that, although commonly used in BCRL research,
SF-36 does not address specific symptoms suffered
by BCRL patients such as heavy and swollen arms.
Only one study82 used a lymphedema-specific qual-
ity of life tool, although this LymphedemaQuestion-
naire was not a validated tool.
One study81 reported on heaviness in the affected
armusing a 10-cm visual line, however, datawere not
reported as average scores but instead represented in
graph format without clear labelling of the axes.
Another study75 assessed heaviness with a self-ratingCOPYRIGHT  2018 THE AUTHORS. PUBLISHED BY 464
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indicating severe symptoms, but did not provide a
subgroup analysis for women with less than
12 months duration of BCRL symptoms. Data for
this outcome were excluded from the review.
Two studies35,81 reported arm function using two
different methods. One study81 used a visual analog
scale with a 10-cm line to measure participant per-
ception of range of motion, although data were not
reported as average scores but instead represented in
graph format without clear labelling of the axes. The
other study35 used the Disabilities of the Arm Shoul-
der and Hand questionnaire (DASH). These func-
tional tools are not comparable.
Only two studies81,82 addressed patient-perceived
satisfaction with treatment: Kaviani et al.81 used a
visual analog scale with a 10cm line to determine
the participant’s desire to continue with low level laser
therapy;Gradalski et al.82usedanumerical rating scale
to determine satisfaction with treatment by assessing
quality of life (0¼ least to 10¼best quality of life).
Wide heterogeneity in study populations, inter-
ventions and measurement outcomes made mean-
ingful comparison difficult and meant meta-analysis
could not be conducted.
Length of follow-up
Despite the chronicity of lymphedema and potential
for treatment failure post intervention,90 the long-
term impact of the intervention was reported by onlyTable 5: Results for studies reporting excess arm vo
Study Method
Number of
participants
Complex decongestive treatment (CDT/DLT)
Dayes et al. 201335,a
DLT groupb,c
Control groupb,c
Manual
circumference
measurement
31
23
Gradalski et al. 201582
CDT groupb,d
CB group
Manual
circumference
measurement
25
z
Hwang et al. 201379
CDT group 1 (<20%EAV)b,d
CDT group 2 (20%EAV)
Perometer
32
z
EAV¼ excess arm volume.
zData not presented: mean breast cancer-related lymphedema (BCRL) duration >9 m
aData provided by corresponding author.
bData presented as relative (%) EAV, i.e. swollen armvolume-non swollen arm volumenon-swollen arm volume
  100.
cSubgroup of women with BCRL duration <12months.
dMean BCRL duration 9 months.
ep> .05 between group difference.
fp< .05 within group difference.
gNo p values reported.
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tored participants for six months post intervention,
Dayes et al.35 monitored for one year and Hwang
et al.79 for two years. The other four studies36,75,80,81
did not monitor the effect of treatment beyond the
completion of the intervention period.
Review findings
The findings from the seven included stud-
ies35,36,75,79-82 are presented below, reported accord-
ing to intervention for the primary outcomes of
interest relating to excess arm volume and patient-
centered outcomes. Results for each outcome are
presented only for subgroups of participants
with reported BCRL duration of less than
12 months35,36,82 and intervention groups where
mean BCRL symptom duration is no more than
9 months;79-81 no study recruited only women with
BCRL symptoms duration less than 12 months.
Complex decongestive therapy
Four studies35,75,79,82 (n¼152) reported some imme-
diatepost intervention reduction in excess armvolume;
the other study80 involving CDT did not measure
relative excess limb volume. Table 5 presents the
reduction as absolute excess arm volume (ml)82 or
relative (%) excess arm volume,35,79 and Table 6
presents the relative (%) change in excess arm vol-
ume;35,75,82 long-term follow-up data are also shown
for one study.35lume (ml)
(n)
Pre-intervention
EAV
Post-intervention
EAV
Final reported
EAV
23%12
21%7
17%12e
12%12e
15%15e
15%13e
898445
z
472285e,f
z
506263e
z
11%5
z
10%9g
z
14%11g
z
onths.
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Table 6: Results for studies reporting percentage reduction in excess arm volume
Study
Duration of
intervention
(weeks)
Number of
participants
(n)
Measurement
method
Mean % EAV
reduction post-
intervention
Mean %EAV
reduction at
week 4–7
Mean %EAV
reduction at
3 months
Mean %EAV
reduction at
6 months
Mean %EAV
reduction at
1 year
Complex decongestive treatment (CDT/DLT)
Dayes et al.
201335,b
DLT groupc
Control groupc
4 31
23
Manual
circumference
2847e
4257e
2945e
2825e
3635e
3846e
4535e
3834e
3664e
3751e
Gradalski et al.
201582
CDT groupd
CB group
2 25
z
Manual
circumference
Reported: 47%
relative volume
change87,f
z
Haghighat et al.
201375,b
CDT groupc 2–3 60
Water
displacement
4613g
- - - -
Compression bandaging (CB) and manual lymph drainage (MLD)
McNeely et al.
200436 z
CBRMLD groupc
CB groupc
4 8
10
Water
displacement
56z g,h
47z g,h
8
10
Manual
circumference
62z g,h
44z g,h
EAV¼ excess arm volume.
zaPercentage reduction in EAV calculated as pre interventionEAV-post interventionEAVpre interventionEAV
 
 100.
bData provided by corresponding author.
cSubgroup of women with BCRL duration <12months.
dMean BCRL duration 9 months.
ep> .05 within group difference.
fp< .05 within group difference.
gNo p values reported.
hData calculated from published graph.
zData not presented: mean BCRL duration >9 months.
SYSTEMATIC REVIEW E. Jeffs et al.Two controlled studies35,82 (n¼79) reported sig-
nificant post intervention reduction in excess arm
volume: Dayes et al.35 reported a greater post inter-
vention reduction in excess arm volume for the self-
treatment group (42%57, n¼23) compared to the
CDT group (2847, n¼31), although there was no
significant between-group difference in reduced
excess arm volume (p>.05) at 12 months follow-
up; Gradalski et al.82 reported a significant post
intervention reduction in excess arm volume for the
CDT group (46%, n¼25) which was retained at six
months follow-up.One uncontrolled study75 (n¼60)
reported (by personal communication) a 46% post
intervention reduction in excess armvolume,whereas
the other79 (n¼32) reported an unchanged relative
arm volume at six months follow-up for women with
a baseline of less than 20% excess arm volume. The
limited available data precluded subgroup compari-
son by severity of BCRL symptoms.
Only two studies35,79 provided long-term follow-
up, with one controlled study35 reporting retention
of intervention benefit and further improvement inJBI Database of Systematic Reviews and Implementation Reports
WOLTERS KLUWER HEALTHboth groups over a 12-month period, and the other
uncontrolled study79 reporting a non-significant
increase in percentage excess arm volume over the
subsequent two-year period; a third study82 reported
retention of treatment benefit at six months post
intervention, however there was no statistically sig-
nificant difference to the other intervention group
(compression bandaging) whose outcomes are not
reported here as duration of BCRL symptoms was a
mean of 9.410.2 months.
Gradalski et al.82 (n¼25) reported a statistically
significant post intervention improvement in lymph-
edema-specific quality of life of 1.69 points (on a 10-
point scale), although the clinical meaningfulness of
this is unknown.One study35 (n¼54) reportednopost
intervention improvement in health-related quality of
life in either group, although below average health
status (SF-36 summary scores<50) was recorded pre
and post intervention for both the whole study sample
(n¼98) and the subgroupofwomenwith<12months
duration of BCRL (n¼54). Another study80 (n¼ 40)
reported a statistically significant post interventionCOPYRIGHT  2018 THE AUTHORS. PUBLISHED BY 466
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Table 7: Results for studies reporting Short FormHealth Survey (SF-36) Physical Component summary score
Study
Number of
participants (n)
Mean pre-intervention
score
Mean post-intervention
score
Complex decongestive treatment (DLT)
Dayes et al. 201335,a,b
DLT group
Control group
31
24
42.97.5
44.66.8
45.17.3 (n¼39)d
44.86.3 (n¼22)d
Complex decongestive physiotherapy (CDPT) and active resistive exercise (ARE)
Kim et al. 201080,c
CDPTRARE group
CDPT group
20
20
68.2517.42
68.5011.01
85.1213.89e
76.0012.73e
aData provided by corresponding author.
bSubgroup of women with BCRL duration <12 months.
cMean BCRL duration 9 months.
dp> .05 for all change score comparisons.
ep< .05 according to repeated-measures analysis of variance between pre and post treatment in each group.
SYSTEMATIC REVIEW E. Jeffs et al.improvement in SF-36 scores in both groups with a
greater improvement in the CDT plus active resistive
exercise group compared to CDT alone (p<.05). The
findings are presented in Tables 7 and 8.
Dayes et al.35 reported non-significant improve-
ment to arm function (DASH scores) in both groups.
The other study81 assessing function did not report
average self-rating scores as average scores.
Data for the effect of treatment on heaviness in
the affected arm were not included in this review:
one study81 did not report data as average scores and
the other75 reported data only for the whole study
sample including women withmore than 12 months
BCRL duration.Table 8: Results for studies reportingShort FormHealt
Study
Number of
participants (n)
M
Complex decongestive treatment (DLT)
Dayes et al. 201335,a,b
DLT group
Control group
31
24
Complex decongestive physiotherapy (CDPT) and a
Kim et al. 201080,c
CDPTRARE group
CDPT group
20
20
aData provided by corresponding author.
bSubgroup of women with BCRL duration <12 months.
cMean BCRL duration 9 months.
dp> .05 for all change score comparisons.
ep< .05 according to repeated-measures analysis of variance between pre and post t
JBI Database of Systematic Reviews and Implementation Reports
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reported by one controlled study82 (n¼25) although
the between group difference was not statistically
significant: the CDT group scored 9.4, with 10
representing highest satisfaction with treatment,
and the compression bandaging group scored 8.8.
Compression bandaging and manual lymph
drainage
McNeely et al.36 (n¼18) reported in graphical for-
mat a post intervention percentage reduction in
excess arm volume for women with 11 months
BCRL duration: 56% reduction for the combined
intervention and 47% for compression bandaginghSurvey (SF-36)MentalComponent summary score
ean pre-intervention
score
Mean post-intervention
score
43.75.8
42.96.0
43.94.3 (n¼39)d
44.96.4 (n¼22)d
ctive resistive exercise (ARE)
66.2515.12
64.2516.85
75.2514.73e
69.5017.63e
reatment in each group.
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SYSTEMATIC REVIEW E. Jeffs et al.alone; this reduction was significantly greater than
that achieved by women with 1 year BCRL dura-
tion ( p<0.05).
Exercise
Kim et al.80 (n¼40) reported only one relevant
outcome of interest: health-related quality of life
using SF-36 summary scores to derive physical
and mental health component scores (Tables 7
and 8); they also measured arm volume but reported
only the treated (ipsilateral) arm volume, so the
findings were not considered by this review.
Kim et al.80 recorded a statistically significant
improvement in both groups for the components
of physical andmental health; the intervention group
showed a greater improvement in physical and men-
tal health (9 and 5 extra points respectively) com-
pared to the control group, but the clinical
significance of this improvement is not reported.
However, it should be noted that Ware et al.88
reported SF-36 summary measures with confidenceTable 9: Summary of individual study findings for w
symptom duration <12 months
Citation Excess arm volume HRQOL H
Complex decongestive treatment (CDT/DLT)
Dayes et al. 201335,a
DLT groupb
Control groupb
Y
Y
O
O
Gradalski et al. 201582
CDT groupc
CB group
Y
z
Y
z
Haghighat et al. 201375,a
CDT groupb Y No
Hwang et al. 201379
CDT group 1 (<20% ELV)c
CDT group 2 (20% ELV)
O
z
Compression bandaging (CB) and manual lymph drainage (MLD
McNeely et al. 200436,
CBRMLD groupb
CB groupb
Y
Y
Complex decongestive physiotherapy (CDPT) and active resistive
Kim et al. 201080
CDPTRARE groupc
CDPT groupc
Y
Y
Low level laser therapy
Kaviani et al. 200681
Laser groupc
Sham groupc
Y ¼ improved; O ¼ unchanged; N ¼ worse; ? ¼ data unclear.
aData provided by corresponding author.
bSubgroup of women with BCRL duration <12months.
cMean breast cancer-related lymphedema duration 9 months.
z¼data not presented: mean BCRL duration >9 months.
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WOLTERS KLUWER HEALTHintervals of  6–7 points, which suggests that the
SF-36 findings reported by Kim et al.80 may not be
clinically significant. Participants in this study80
reported better pre-intervention health status (score
65) than Dayes et al.35
Low level laser therapy
Kaviani et al.81 (n¼8) reported women’s self-rating
of arm heaviness and desire to continue with low
level laser therapy in graphical format which lacked
explanatory detail. The graphs appear to record a
slight increase in arm heaviness for laser intervention
and slight reduction in arm heaviness with sham
laser, and a willingness to continue the laser inter-
vention but not sham laser.
In summary, there is some evidence (grade B) that
decongestive treatments effectively reduce lymph-
edema in women with early BCRL (i.e. duration of
<12 months or a mean of nine months), whether
provided as CDT or compression bandaging with or
without MLD (see Table 9). As each study reportedomen with breast cancer-related lymphedema
eaviness Arm function Patient benefit Group difference p
O
O
>.05
Y
z
>.05
z
t reported Not applicable
Not applicable
)
Not reported
exercise (ARE)
>.05
?
?
?
?
Not reported
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able to determine the most effective combination
of treatment elements to reduce excess arm volume
or improve patient-centered outcomes for women
with BCRL duration of less than 12 months. There
wasweak evidence (grade B) for the addition of active
resistive exercise to enhance the benefit of CDT.
Evidence (grade B) for the benefit of low level laser
therapy or intermittent compression therapy for this
population is inconclusive. Evidence was lacking for
the long-term benefit of decongestive treatment for
this population, and the heterogeneity of the treat-
ment protocols precludes the comparison of treat-
ment findings and thus identification of the most
effective treatment for this population.
Discussion
The aim of this review was to identify the effect of
decongestive lymphedema treatment on excess arm
volume and patient-centered outcomes for women
presenting within either 12 months or a mean of nine
months of developing a swollen arm due to BCRL. A
key challenge was the limited number of published
studies that have measured and reported results of
treatment for womenwith early BCRL. Although it is
likely that earlier treatment will result in better out-
comes,12,91-93 this review cannot recommend what
form this treatment should take. Furthermore, no
study focused specifically on this group of women,
nordidanypublishedprotocol forongoingor recently
completed studies refer to the recruitment of women
within 12 months of developing BCRL symptoms.
Two-phase CDT is considered by clinical
experts12,14,94 to be the recommended treatment for
lymphedema, supported by the findings of a review of
systematic reviews.27 This review found some evi-
dence for the effect of CDT to reduce arm volume,
as four studies35,36,75,82 reported a statistically signif-
icant post intervention reduction; however, Dayes
et al.35 reported a significantly greater arm volume
reduction with self-treatment on completion of the
three-week intervention period, although there was
no statistically significant difference in volume reduc-
tionbetween thegroups at sixweeksor 12months.To
date, Dayes et al.35 is the only randomized controlled
trial to compare an intensive therapist-delivered treat-
ment phasewith self-treatment to decongest a swollen
arm,with findings contrary to clinical expectations of
a greater improvement with CDT. Further research is
necessary to determine whether women could benefitJBI Database of Systematic Reviews and Implementation Reports
WOLTERS KLUWER HEALTHfrom costlier intensive treatment or achieve similar
outcomes with more convenient and less resource
intense self-management. The recent move towards
surveillance of women following breast cancer treat-
ment, with the potential to introduce treatment at a
pre-clinical stage,19 does not preclude a need to deter-
mine the most effective – and cost-effective – treat-
ment for women who present with clinical symptoms
of BCRL.
As with previous reviews,17,21,22,27 we found het-
erogeneity of interventions and assessment methods,
and variations in quality of study design and report-
ing, which limited comparison of results. The varia-
tion in treatment protocols emerged as a major
limitation of the review, with no comparative pro-
tocols identified to address the two aspects of the
review question: the most effective treatment ele-
ments and optimal duration of treatment. Despite
the chronicity of lymphedema and potential for
treatment failure post intervention reported else-
where,90 most researchers did not report the long-
term impact of the intervention or treatment failure.
The review findings support those of previous
reviews17,21,22,27 that studies are underpowered
and lack sufficient follow-up.
The priority outcomes and measurement methods
which are meaningful to women and practitioners
have yet to be determined,27 although a survey of 421
Australianswithdifferent typesof lymphedema found
that 60% of participants considered reductions in
swelling, heaviness and tightness, and improvement
in range of movement to be very important treatment
outcomes.95 The effect of treatment has primarily
been measured by changes to limb volume, however
there was no consensus regarding a standardized
format to ensure that a comparison could be made
between different protocols; this is reflective of the
published research into lymphoedema treatments.94
Similarly, there was wide variation in the patient-
centered outcomes measured and methods used.
Although the statistical significance of findings was
reported for some study results, the importance of
these findings for patients and practitioners was not
reported; the minimal clinically important change is
not known, either for objective measures such as
changes in arm volume or subjective measures of
changes to patient symptoms or quality of life.
A strength of this review was the inclusivity of
literature from a wide range of databases with no
restriction to date or language of publication. It isCOPYRIGHT  2018 THE AUTHORS. PUBLISHED BY 469
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published in journals that do not provide an English
abstract, although additional resources would be
required to search databases where there is no
English abstract. No studies were found which
recruited only women with no more than 12 months
duration of BCRL symptoms, which was a limitation
of the review. However, data were obtained from
three studies with published outcomes for subgroups
of women with BCRL duration of less than
12 months35,36,75 and, where it was not possible
to access raw data to determine actual duration of
BCRL, an inclusion criteria of mean BCRL duration
of 9 months likely limited the number of partic-
ipants with >1 year duration of BCRL.79-82
Conclusion
There was weak evidence (grade B) for the impact of
decongestive lymphedema treatment for women
with early BCRL (i.e. duration of <12 months or
a mean of nine months). It was not possible to
identify the optimal treatment components to reduce
excess arm volume or improve patient-centered out-
comes for these women, nor to determine the opti-
mal duration of treatment. The lack of comparable
treatment protocols across studies did not allow any
conclusions to be drawn about the most effective
treatment to be offered to women when they first
present for lymphedema treatment.
Recommendations for practice
There was no evidence to justify change to current
practice.
Recommendations for research
Future primary research needs to focus on the most
effective, acceptable and cost-effective treatment for
women when they first present with BCRL symp-
toms, that is, treatment provided within 12 months
of developing symptoms. Studies should be ade-
quately powered and recruit women exclusively with
less than 12 months duration of BCRL symptoms so
that true inferences about the population of interest
can be drawn from the results obtained.
A consistent method of reporting outcomes is
necessary to permit comparison between studies
and meta-analysis in order to build the evidence
base. Change in excess arm volume should be con-
sidered a key outcome measure and reported as
a percentage of baseline excess arm volume.JBI Database of Systematic Reviews and Implementation Reports
WOLTERS KLUWER HEALTHCollaborations should be encouraged between
groups of lymphedema researchers, particularly with
regard to creating comparable treatment protocols,
outcome measures and reporting methods. Inclusion
of womenwith BCRL in designing studies could help
to identify priority outcomes and select appropriate
patient reported outcome measures.
Studies should include longer follow-up times to
monitor the benefit of treatment in the months fol-
lowing completion of the intervention. Lymphedema
is a chronic condition and studies should identify the
proportion of participants achieving treatment failure
as well as those achieving sustained success.
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Search strategy
1. lymphoedema OR lymphedema OR lymphoedemas or lymphedemas - in title, abstract, subject
heading or keyword
2. breast AND (cancer OR carcinoma OR tumour OR tumor OR malignancy OR neoplasm) - in title,
abstract, subject heading or keyword
3. mastectomy - in title, abstract, subject heading or keyword
4. 2 OR 3
5. 1 AND 4
6. (lymphoedema OR lymphedema OR lymphoedemas or lymphedemas) AND ’review’, in the title only
7. 5 OR 6.
The following databases were searched on July 6, 2016 (unless stated otherwise) to identify studies published
in the commercial literature.Allied and Contemporary Medicine (AMED)JSearch
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tumor) OR (breast carcinoma) OR (breast neoplasm) OR mastectomy).ti,ab16463 exp BREAST NEOPLASMS/ 12254 exp LYMPHEDEMA/ 2255 ((lymphoedema OR lymphedema OR lymphoedemas OR lymphedemas)
AND review).ti86 1 OR 4 2927 2 OR 3 18218 6 AND 7 1199 5 OR 8 123Biomed Central: searched on July 1, 2015Search
number Parameters Results1 (((cancer OR malignancy OR tumour OR tumor OR neoplasm OR
carcinoma[TW]) AND (breast[TW])) AND (lymphoedema OR lymphedema
OR lymphoedemas OR lymphedemas[TW])) OR (mastectomy[TW] AND
(lymphoedema OR lymphedema OR lymphoedemas OR lymphede-
mas[TW])) OR ((lymphoedema OR lymphedema OR lymphoedemas OR
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carcinoma)
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Indexes¼BCI Timespan¼All years208,4413 #2 AND #1
Indexes¼BCI Timespan¼All years178,3674 TS¼mastectomy
Indexes¼BCI Timespan¼All years7,9895 #4 OR #3
Indexes¼BCI Timespan¼All years179,3136 TS¼ (lymphoedema OR lymphedema OR lymphoedemas OR lymphedemas)
Indexes¼BCI Timespan¼All years2,4747 #6 AND #5
Indexes¼BCI Timespan¼All years5208 TI¼ (cancer OR malignancy OR tumour OR tumor OR neoplasm OR
carcinoma)
Indexes¼BCI Timespan¼All years790,0479 TI¼breast
Indexes¼BCI Timespan¼All years114,94110 #9 AND #8
Indexes¼BCI Timespan¼All years92,94911 TI¼mastectomy
Indexes¼BCI Timespan¼All years1,78212 #11 OR #10
Indexes¼BCI Timespan¼All years94,00813 TI¼ (lymphoedema OR lymphedema OR lymphoedemas OR lymphedemas)
Indexes¼BCI Timespan¼All years1,12714 #13 AND #12
Indexes¼BCI Timespan¼All years14315 #14 OR #7
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ti,ab5102 ((Breast cancer) OR (breast malignancy) OR (breast tumour) OR (breast
tumor) OR (breast carcinoma) OR (breast neoplasm) OR mastectomy).ti,ab35983 exp LYMPHOEDEMA/ 5024 exp BREAST CANCER/ 27965 ((lymphoedema OR lymphedema OR lymphoedemas OR lymphedemas)
AND review).ti96 1 OR 3 5647 2 OR 4 37428 6 AND 7 1379 5 OR 8 144CINAHLSearch
number Parameters Results1 (lymphoedema OR lymphedema OR lymphoedemas OR lymphedemas).
ti,ab14012 ((Breast cancer) OR (breast malignancy) OR (breast tumour) OR (breast
tumor) OR (breast carcinoma) OR (breast neoplasm) OR mastectomy).ti,ab320363 exp LYMPHEDEMA/ 18614 exp BREAST NEOPLASMS/ 393085 ((lymphoedema OR lymphedema OR lymphoedemas OR lymphedemas)
AND review).ti466 1 OR 3 20637 2 OR 4 450308 6 AND 7 7369 5 OR 8 757Cochrane LibrarySearch
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number Parameters Results1 exp lymphedema/ 165222 lymphedema?.mp. [mp¼ title, abstract, heading word, drug trade name,
original title, device manufacturer, drug manufacturer, device trade name,
keyword]152133 1 or 2 180394 exp breast cancer/ 3509075 exp breast tumor/ 4209656 exp breast carcinoma/ 595627 (breast adj3 cancer).mp. [mp¼ title, abstract, heading word, drug trade
name, original title, device manufacturer, drug manufacturer, device trade
name, keyword]3817968 (breast adj3 tumor).mp. [mp¼ title, abstract, heading word, drug trade
name, original title, device manufacturer, drug manufacturer, device trade
name, keyword]988719 (breast adj3 malignancy).mp. [mp¼ title, abstract, heading word, drug
trade name, original title, device manufacturer, drug manufacturer, device
trade name, keyword]1575D BY 478
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name, keyword]7725011 (breast adj3 neoplasm).mp. [mp¼ title, abstract, heading word, drug trade
name, original title, device manufacturer, drug manufacturer, device trade
name, keyword]165712 mastectomy.mp. 4991613 (lymphedema? and review).ti. 16014 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 47209815 3 and 14 400916 13 or 15 4112HMICSearch
number Parameters Results1 (breast adj3 cancer).mp. [mp¼ title, other title, abstract, heading words] 2605
2 (breast adj3 tumor).mp. [mp¼ title, other title, abstract, heading words] 22
3 (breast adj3 malignancy).mp. [mp¼ title, other title, abstract, heading
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14 (breast adj3 carcinoma).mp. [mp¼ title, other title, abstract, heading
words]275 (breast adj3 neoplasm).mp. [mp¼ title, other title, abstract, heading words] 0
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substance word, subject heading word, keyword heading word, protocol
supplementary concept word, rare disease supplementary concept word,
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supplementary concept word, rare disease supplementary concept word,
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substance word, subject heading word, keyword heading word, protocol
supplementary concept word, rare disease supplementary concept word,
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substance word, subject heading word, keyword heading word, protocol
supplementary concept word, rare disease supplementary concept word,
unique identifier]404056 (breast adj3 neoplasm).mp. [mp¼ title, abstract, original title, name of
substance word, subject heading word, keyword heading word, protocol
supplementary concept word, rare disease supplementary concept word,
unique identifier]5607 mastectomy.mp. 325478 1 or 2 or 3 or 4 or 5 or 6 or 7 3091919 exp Lymphedema/ 1023510 lymphedema?.mp. [mp¼ title, abstract, original title, name of substance
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5 (breast adj3 neoplasm).mp. [mp¼ title, abstract, full text, caption text] 2
6 mastectomy.mp. 2167 lymphedema?.mp. [mp¼ title, abstract, full text, caption text] 15
8 (lymphedema? and review).ti. 09 1 or 2 or 3 or 4 or 5 or 6 141310 7 and 9 1511 8 or 10 15PsycINFOSearch
number Parameters Results1 exp Breast Neoplasms/ 80402 (breast adj3 cancer).mp. [mp¼ title, abstract, heading word, table of
contents, key concepts, original title, tests & measures]105643 (breast adj3 tumor).mp. [mp¼ title, abstract, heading word, table of
contents, key concepts, original title, tests & measures]694 (breast adj3 malignancy).mp. [mp¼ title, abstract, heading word, table of
contents, key concepts, original title, tests & measures]135 (breast adj3 carcinoma).mp. [mp¼ title, abstract, heading word, table of
contents, key concepts, original title, tests & measures]1306 (breast adj3 neoplasm).mp. [mp¼ title, abstract, heading word, table of
contents, key concepts, original title, tests & measures]167 mastectomy.mp. 7508 1 or 2 or 3 or 4 or 5 or 6 or 7 110849 lymphedema?.mp. [mp¼ title, abstract, heading word, table of contents,
key concepts, original title, tests & measures]15810 lymphedema?.ti. 8011 review.ti. 13074612 8 and 9 9913 10 and 11 814 12 or 13 101D BY 481
ITUTE.
SYSTEMATIC REVIEW E. Jeffs et al.PubMedJSearch
numberBI Database of SyParametersstematic Reviews and Implementation Reports COPYRIGHT  2018 THE AUTHORS. PUBLISHE
WOLTERS KLUWER HEALTH, INC. ON BEHALF OF THE JOANNA BRIGGS INSTResults1 Search mastectomy[Title] 52842 Search (breast cancer[MeSH Terms]) OR mastectomies[MeSH Terms] 2431143 Search (breast[Title/Abstract]) AND (neoplasm[Title/Abstract] OR neo-
plasms[Title/Abstract] OR carcinoma[Title/Abstract] OR cancer[Title/
Abstract] OR tumour[Title/Abstract] OR tumor[Title/Abstract] OR malig-
nancy[Title/Abstract] OR malignancies[Title/Abstract])2702444 Search (((lymphedema[Title/Abstract] OR lymphedemas[Title/Abstract] OR
lymphoedema[Title/Abstract] OR lymphoedemas[Title/Abstract])) OR lym-
phedema[MeSH Terms]) OR lymphedemas[MeSH Terms]125315 Search (review[Title]) AND ((((lymphedema[Title/Abstract] OR lymphede-
mas[Title/Abstract] OR lymphoedema[Title/Abstract] OR lymphoedemas[-
Title/Abstract])) OR lymphedema[MeSH Terms]) OR lymphedemas[MeSH
Terms])3366 Search ((((breast[Title/Abstract]) AND (neoplasm[Title/Abstract] OR neo-
plasms[Title/Abstract] OR carcinoma[Title/Abstract] OR cancer[Title/
Abstract] OR tumour[Title/Abstract] OR tumor[Title/Abstract] OR malig-
nancy[Title/Abstract] OR malignancies[Title/Abstract]))) OR ((breast can-
cer[MeSH Terms]) OR mastectomies[MeSH Terms])) OR
mastectomy[Title]3248947 Search ((((((breast[Title/Abstract]) AND (neoplasm[Title/Abstract] OR neo-
plasms[Title/Abstract] OR carcinoma[Title/Abstract] OR cancer[Title/
Abstract] OR tumour[Title/Abstract] OR tumor[Title/Abstract] OR malig-
nancy[Title/Abstract] OR malignancies[Title/Abstract]))) OR ((breast can-
cer[MeSH Terms]) OR mastectomies[MeSH Terms])) OR
mastectomy[Title])) AND ((((lymphedema[Title/Abstract] OR lymphede-
mas[Title/Abstract] OR lymphoedema[Title/Abstract] OR lymphoedemas[-
Title/Abstract])) OR lymphedema[MeSH Terms]) OR lymphedemas[MeSH
Terms])24538 Search ((((((mastectomy[Title]) OR ((breast cancer[MeSH Terms]) OR
mastectomies[MeSH Terms])) OR ((breast[Title/Abstract]) AND (neo-
plasm[Title/Abstract] OR neoplasms[Title/Abstract] OR cancer[Title/
Abstract] OR carcinoma[Title/Abstract] OR tumour[Title/Abstract] OR
tumor[Title/Abstract] OR malignancy[Title/Abstract])))) AND ((((lymphe-
dema[Title/Abstract] OR lymphoedema[Title/Abstract] OR lymphedemas[-
Title/Abstract] OR lymphoedemas[Title/Abstract])) OR lymphedema[MeSH
Terms]) OR lymphedemas[MeSH Terms]))) OR ((review[Title]) AND
((((lymphedema[Title/Abstract] OR lymphoedema[Title/Abstract] OR lym-
phedemas[Title/Abstract] OR lymphoedemas[Title/Abstract])) OR lymphe-
dema[MeSH Terms]) OR lymphedemas[MeSH Terms]))2680D BY 482
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OR lymphoedemas OR lymphedemas)) OR (TITLE(lymphoedema OR
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number Parameters Results1 ((((title:cancer or malignancy or tumour or tumor or neoplasm or
carcinoma) and (title:breast)) or (title:mastectomy)) and (title:lymphoedema
or lymphedema)) or ((title:lymphoedema or lymphedema) and
(title:review))257Web of ScienceSearch
number Parameters Results1 TS¼mastectomy OR TI¼mastectomy
Indexes¼ SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH, ESCI
Timespan¼1900–201618,0652 TI¼ (breast cancer) OR TI¼ (breast malignancy) OR TI¼ (breast tumour)
OR TI¼ (breast tumor) OR TI¼ (breast neoplasm) OR TI¼ (breast
carcinoma)216,1873 TS¼ (breast cancer) OR TS¼ (breast malignancy) OR TS¼ (breast tumour)
OR TS¼ (breast tumor) OR TS¼ (breast neoplasm) OR TS¼ (breast
carcinoma)453,3984 #3 OR #2 OR #1 457,4365 TS¼ (lymphoedema OR lymphedema OR lymphoedemas OR lymphedemas) 7,406
6 TI¼ (lymphoedema OR lymphedema OR lymphoedemas OR lymphedemas) 4,241
7 #6 OR #5 7,4068 #7 AND #4 2,2469 TI¼ review 423,134
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Whelan,T.
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Kligman,L.
Reise,D.
LeBlanc,L.
McNeely,M.
Manchul,L.
Wierjikowski,J.
Levine,M.
201335,a,bRandom-
ized con-
trolled trialExcess limb
volume by cir-
cumference
measurement.
Quality of life,
by SF-36.
Functional sta-
tus, by Disabil-
ities of the
Arm, Shoulder
and Hand ques-
tionnaire
(DASH).
Outcomes mea-
sured by study
assessor blinded
to treatment
allocation;
training of
assessor not
reported.2 weeks
and
48 weeks58 women from a study
population of 103
women.
Lymphedema defined as
>10% ELV.
Age ranged from 36–86
years; mean age of 61
years in DLT group and
59 years in control group.
58 women had BCRL
duration of <1 year, and
44 women had duration
1 year.
Study setting: 6 regional
cancer centers in Canada.
Recruitment: March 2003
- February 2009.I1: DLT.
MLD (Vodder / Foldi
method) & short
stretch compression
bandaging. Then
maintenance phase
with elastic compres-
sion garments (30–
40mmHG) worn 12
hours per day (wak-
ing hours).
C:
compression gar-
ments worn as per
maintenance phase
above.
Both groups: advice
re skin care, exercise
(not specified) &
maintenance of
healthy body weight.I1: DLT.
4 weeks daily
treatment of 1
hour MLD
(Mon-Fri),
short stretch
compression
bandaging, and
self-bandaging
at weekend. (20
sessions)
C:
Hosiery 12
hours/day, 30–
40mmHg.
Both groups
received advice
re skin care,
exercise, main-
taining healthy
body weight.I1: DLT.
Therapists certi-
fied in either
Vodder or Foldi
lymphedema
schools.
Patient taught
to self-apply
short stretch
bandages at
weekend.
Maintenance
treatment per-
formed by the
patient.
C: patientPopulation included
women with mean
duration >1 year.
Author provided
data for those 58
women with dura-
tion <1 year.
No data re number
of women who had
received previous
BCRL treatment.
BCRL severity data
provided.
Clear reporting of
data collected at fol-
low-up with varia-
tion in number of
participants com-
pleting each assess-
ment.Gradalski,T.
Ochalek, K.
Kurpiewska,J.
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ized con-
trolled trialExcess limb
volume by cir-
cumference
measurement.
Lymphedema-
specific quality
of life, by non-
validated ques-
tionnaire. Satis-
faction with
treatment, by
numerical rat-
ing scale.
Therapist
blinded to pre-
vious measure-
ments but not
to treatment
allocation;
training of
assessor not
reported.6 month 51 women with mean age
of 61 years for CDT (SD
9.2; n¼25) and 62 years
for CB (SD 12.2; n¼26).
Breast cancer treatment:
not reported.
Lymphedema defined as
20% difference between
limb volumes.
BCRL duration: mean 8.3
months for CBþMLD
group (SD 7.2) and 9.4
months for CB group (SD
10.2). Excluded if prior
physiotherapy for arm
lymphedema.
Study setting: unspecified
treatment facility in
Poland.
Recruitment: 1 May 2010
– 31 December 2012.IG1: CDT.c
Compression bandage
plus MLD
(CBþMLD) group.
Multi-layer compres-
sion bandaging
(MLCB) with gradi-
ent pressure; sub-
bandage pressure
20–30 mmHg:
 Cotton liner
 Gauze layer
 Foam pad layer
(product
specified)
 3 short-stretch
bandage layers
(product speci-
fied), from hand,
then wrist, then
below elbow.
Plus Vodder II
method MLD.
I2: CB.d
CB group. MLCB (as
above).
Both groups: speci-
fied exercises & deep
breathing while
wearing MLCB.
Then maintenance
phase with flat-knit
compression garment
(strength not speci-
fied) waking hours,
exercise, arm and
skin care.IG1: CDT.c
2 weeks daily
treatment Mon-
day-Friday (10
sessions), with
30 mins MLD
and bandages.
I2: CB.d
2 weeks daily
treatment (10
sessions), with
bandages only.
Both groups:
bandages left in
place until next
treatment.
Exercises done
10–15 minutes
once per day
during CDT.
Followed by 6
months daily
self-care (main-
tenance phase):
10–15 mins
exercises 2x/
day while wear-
ing hosiery.Two PTs expe-
rienced in
lymphedema
performed and
supervised ther-
apy and mea-
surement in
both groups
and in both
phases of treat-
ment.
Practitioners
being super-
vised are not
specified.Defined BCRL as
20% ELV, which
is more conservative
definition than used
by other studies. No
report of severity of
lymphedema.
Used lymphedema-
specific but non-
validated quality of
life tool.
Data for non-swol-
len limb not pro-
vided so cannot
calculate %volume
change for
comparison
with other
studies.D BY 502
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Duration and
frequency Delivered byHaghighat,S.
Lotfi-Tokalda-
ny,A.
Maboudi,A.
Karami,M.
Bahadori,A.
Weiss,J.
201375,a,bDescriptive
study:
Prospective
case seriesExcess limb
volume by
water displace-
ment.
Heaviness, by
VAS.
No report of
person perform-
ing assessments.
Also reported
outcomes not
considered by
this review:
pain and pares-
thesia, assessed
by VAS.0 weeks 60 women from a study
population of 137 women
with mean age of 54,
range 26–84 years. Breast
cancer treatment included
radiotherapy for 124
women. Lymphedema def-
inition: not provided. 84
women had BCRL dura-
tion 2 years and 53 had
duration >2 years; per-
sonal communication
from authors reported 60
women (44%) with dura-
tion <12 months. 111
women had undergone
modified radical mastec-
tomy and 26 had breast
preservation; 124 women
received radiotherapy.
Study setting was Iranian
Breast Cancer Center
Lymphedema Clinic in
Tehran, Iran.
Recruitment: 2008 (date
range not specified).I: CDT.
skin care, 45 minutes
Vodder method
MLD, remedial
exercises (not
specified), multi-layer
short-stretch
compression bandag-
ing (materials
specified).
C:
no comparator
group.I: CDT.
2–3 weeks
daily treatment,
Monday-
Friday (10–15
sessions).
C:
no comparator
group.Not reported. No previous BCRL
treatment.
BCRL definition
and severity not
provided.
Author personal
communication re
number of women
<1yr BCRL dura-
tion, but no data.Hwang,J.M.
Hwang,J.H.
Kim,T.
Lee,S.
Chang,H.
Chu,I.
201379,cDescriptive
study:
Retrospec-
tive case
series
reviewExcess limb
volume, by
Perometry mea-
surements
Assessor experi-
enced in lymph-
edema treat-
ment; training
not reported.24 month 32 women from a study
population of 57 women
with mean age of 49 years
(10.3). Breast cancer
treatment included axil-
lary node dissection.
Lymphedema definition
not provided. BCRL dura-
tion: mean 8.5 months
(6.6) for women with
<20% ELV (n¼ 32) and
27.5 months (31.5) for
20% ELV.
Study setting: Department
of Physical and Rehabili-
tation Medicine in Seoul,
Korea.
Recruitment: retrospective
chart review performed
for patients treated
between 1st January 2001
and 30th October 2011.I: CDT.
1 hour MLD (method
not specified), multi-
layer short-stretch
compression bandage
(method not speci-
fied), specific reme-
dial exercises (not
stated), skin care.
Maintenance phase
(post intervention
period): daily self-care
with compression gar-
ments (not specified),
self-MLD (taught by
PT), skin care, reme-
dial exercises (not
specified), plus 3
times per week night-
time self-bandage
(taught by PT).
C:
no comparator group.I: CDT.
2 weeks of daily
CDT, Monday-
Friday (10 ses-
sions). Then
daily self-care
(maintenance
treatment) plus
3 times per
week night-time
self-bandage.
C: no compara-
tor group.Treated by two
certified (not
specified)
skilled PTs.
Post interven-
tion mainte-
nance therapy
by patient.Population included
women with mean
duration >1 year.
No data provided
regarding number of
women who had
previous BCRL
treatment.
BCRL severity
reported as < or
20% ELV.Kaviani,A.
Fateh,M.
Nooraie,R.
Alinagi-
Zadeh,M.
Ataie-Fashta-
mi,L.
200681,cRandom-
ized con-
trolled trialHeaviness by
VAS.
Range of move-
ment by VAS.
Desire to con-
tinue with Rx,
by VAS.
No report of
person perform-
ing assessments.
Also reported
outcome not
considered by
this review:
sum of circum-
ferences.0 weeks 8 women with mean age
of 54 years in laser group
(n¼4) and 49 years in
sham group (n¼4).
Breast cancer treatment:
all women had undergone
modified radical mastec-
tomy and received radio-
therapy. Lymphedema
defined as >10% ELV.
BCRL duration: mean of
7 months for laser group
(SD 3.8) and 6 months
for sham laser group (SD
5.3).
Study setting: Breast Can-
cer Center in Tehran,
Iran.
Recruitment: March 2002
- December 2003.I1: Laser.
Treatment to five
points in axilla at
1 cm distance from
skin, energy density
1.5J/cm2
Laser diode, output
power 10 Watts at
890nm wavelength
in pulsed mode
(product specified).
C: sham laser.
Sham laser under
strictly controlled
double-blinded con-
ditions – sham con-
ditions not specified.I1: Laser.
3 weeks of treat-
ment, 3 times
per week - treat-
ment session
time not speci-
fied -then 8
week break fol-
lowed by 3 more
weeks treatment
as before. Total
18 sessions.
C: sham laser. 3
weeks of sham
treatment, 3
times per week
(session time not
specified), then 8
week break fol-
lowed by 3 more
weeks sham
treatment as
before. Total 18
sessions.Not stated for
either group.No data provided
regarding number of
women who had
received previous
BCRL treatment.
No severity of
BCRL.
The conditions of
this double-blind
controlled trial are
not made explicit.D BY 503
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Duration and
frequency Delivered byKim,D.
Sim,Y.
Jeong,H.
Kim,G.
201080,cRandom-
ized con-
trolled trialQuality of life,
by SF-36.
Interviewer
blinded to
treatment allo-
cation; training
of assessor not
reported.
Also reported
outcome not
considered by
this review: vol-
ume of swollen
limb only.0 weeks 40 women with age range
of 27–76 years; popula-
tion mean age of 51 years
in each group (n¼20 per
group).
Breast cancer treatment:
not described.
Lymphedema defined as
>2 cm difference between
affected and normal arm.
BCRL duration: mean
4.35 months for ARE
group (n¼12.91; range
1–57 months) and 5.24
months for non-ARE
group (12.61; range
0.5–68 months).
Study setting: Department
of Rehabilitation Medi-
cine in Kosin, Korea.
Recruitment: January -
December 2009.I1: CDPTþARE.
CDPT¼MLD
(method not speci-
fied), bandaging,
remedial exercises
(specified) with
breathing exercises.
Self-CDPT¼hosiery
(details not provided)
& remedial exercises.
ARE¼ specified exer-
cise program using
0.5 kg dumb-bell
while wearing ban-
dages or 1 kg dumb-
bell (if tolerated)
while wearing
hosiery.
I2: CDPT.
CDPT and self-
CDPT as above.I1:CDPTþARE
2 weeks daily
CDPT (10 ses-
sions) with
15mins Active
Resistive Exer-
cise (ARE),
then 6 weeks
self-CDPT.
I2: CDPT.
2 weeks daily
CDPT (10 ses-
sions) then 6
weeks self-
CDPT.Both groups:
physical thera-
pist, with self-
administered
CDPT by
patient.
Unclear
whether same
physical thera-
pist treated
both groups.No data provided
regarding number of
women who had
received previous
BCRL treatment.
No severity of
BCRL.McNeely,M.
Magee,D.
Lees,A.
Bagnall,K.
Haykowsky,M.
Hanson,J.
200436,bRandom-
ized con-
trolled trialExcess limb
volume by
water displace-
ment and cir-
cumference
measurement.
Assessments
done by two
independent
PTs, blinded to
treatment allo-
cation and
trained in mea-
surement
method, with
testing for
intra-rater and
inter-rater reli-
ability.0 weeks 18 women from a study
population of 45 women
with age range of 33–87
years: mean age 58 years
in MLDþCB group and
63 years in MLD group.
Breast cancer treatment
included axillary node dis-
section, with 39 also
receiving radiotherapy.
Lymphedema defined as
>150ml ELV.
BCRL duration median
21 months in MLDþCB
group (range 2–219
months) and 19 months in
CB group (range 1–194
months); a subgroup of
18 women had duration
<11 months.
Study setting: Cancer
rehabilitation unit in
Edmonton, Canada.
Recruitment: November
2000 - December 2001.I1: MLDþCB.
Vodder method
MLD plus short
stretch bandages
applied with gradient
pressure using figure
of eight configura-
tion:
 Cotton liner
 Gauze layer to
fingers and hand
 0.5 cm foam pad-
ding layer to
hand and arm
 3–4 bandage
layers, starting
first at hand, then
at wrist, then
below elbow
I2: CB.
Short stretch as per I
group.
Both groups: stan-
dard education re
arm care and skin
care.I1: MLDþCB.
4 weeks daily
treatment,
Monday-Friday
(20 sessions),
with 45 mins
MLD and ban-
dages applied
and left in place
until next
scheduled treat-
ment
I2: CB.
4 weeks daily
treatment,
Monday-Friday
(20 sessions),
with bandages
applied and left
in place until
next scheduled
treatmentI1: MLDþCB:
Bandages
applied by
physical ther-
apy assistant;
MLD by PT
trained in Vod-
der method
I2: CB: physical
therapy assis-
tantPopulation included
women with mean
duration >1 year.
No data provided
regarding number of
women who had
received previous
BCRL treatment.
No severity of
BCRL.
Intra-rater and
inter-rater reliability
testing of indepen-
dent assessor’s mea-
surement technique.adata provided by corresponding author.
bsubgroup of women with BCRL duration <12months.
cmean BCRL duration 9 months.
ddata not presented: mean BCRL duration >9 months.
PT, physiotherapist.D BY 504
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A BRIGGS INSTITUTStudy/
citationCompression
bandaging (CB)Multi-layer compression bandaging applied with gradient
pressure:
 Cotton liner
 Gauze layer to fingers and hand
 Foam padding layer (product specified) to hand and
arm
 3 short stretch bandage layers (product specified),
starting first at hand, then at wrist, then below elbow
Sub-bandage pressure measured and stabilized at 20–
30mmHg.
Also program of active and self-assisted exercises (specified)
performed while wearing bandages, and deep diaphragmatic
breathing;
Followed by maintenance phase using custom-made flat-knit
compression garment (compression strength not specified) dur-
ing waking hours and arm and skin care and exercise program.2 weeks daily treatment,
Monday-Friday (10 sessions),
with bandages applied and
left in place until next sched-
uled treatment.
Followed by 6 months daily
self-care (maintenance
phase).
Exercises performed 10–15
minutes once per day during
CDT and twice per day in
maintenance phase.Qualified phy-
siotherapistsGradalski
et al. 201582Short stretch bandages applied with gradient pressure using
figure of eight configuration:
 Cotton liner
 Gauze layer to fingers and hand
 0.5 cm foam padding layer to hand and arm
 3–4 bandage layers, starting first at hand, then at
wrist, then below elbow
Also standard education re arm care and skin care.4 weeks daily treatment,
Monday-Friday (20 sessions),
with bandages applied and
left in place until next sched-
uled treatmentPhysical therapy
assistantMcNeely
et al. 200436Compression
bandaging þ
manual lymph
drainage (MLD)Vodder method MLD plus short stretch bandages applied
with gradient pressure using figure of eight configuration:
 Cotton liner
 Gauze layer to fingers and hand
 0.5 cm foam padding layer to hand and arm
 3–4 bandage layers, starting first at hand, then at
wrist, then below elbow
Also standard education re arm care and skin care.4 weeks daily treatment,
Monday-Friday (20 sessions),
with 45 mins MLD and ban-
dages applied and left in
place until next scheduled
treatmentBandages applied
by physical ther-
apy assistant;
MLD by physio-
therapist trained
in Vodder methodMcNeely
et al. 200436Compression
therapyElastic compression garments to be worn 12 hours per day
(waking hours), including sleeve (30–40mmHG) and glove.
Advice re skin care, exercise (not specified) and maintenance
of healthy body weight.Daily self-care (maintenance
treatment)Patient. Dayes et al.
201335Complex Decon-
gestive Therapy
(CDT)MLD and short stretch compression bandaging (Vodder or
Foldi method MLD & bandaging).
Advice re skin care, exercise (not specified) and maintenance
of healthy body weight.
Following intensive 4 week treatment period, fitted with
elastic compression garments to be worn daily (waking
hours), including sleeve (30–40mmHG) and glove.4 weeks intensive treatment,
5 days per week (20 ses-
sions), with 1 hour MLD
then bandages applied for 23
hours.
Subsequent maintenance
treatment with daily self-
care, compression garments
worn 12 hours/day.Therapists certi-
fied in either Vod-
der or Foldi
lymphedema
schools.
Patient taught to
self-apply short
stretch bandages at
weekend.
Maintenance treat-
ment performed by
the patient.Dayes et al.
201335Complex Decon-
gestive Therapy
(CDT) continuedMulti-layer compression bandaging applied with gradient
pressure and sub-bandage pressure measured and stabilized
at 20–30mmHg:
 Cotton liner
 Gauze layer to fingers and hand
 Foam padding layer (product specified) to hand and arm
 3 short stretch bandage layers (product specified), starting
first at hand, then at wrist, then below elbow
Plus MLD based on Vodder II method, used with higher
pressures and slower maneuvers than used in less advanced
edema;
Also program of active and self-assisted exercises (speci-
fied) performed while wearing bandages, and deep dia-
phragmatic breathing;
Followed by maintenance phase using custom-made flat-
knit compression garment (compression strength not speci-
fied) during waking hours and arm and skin care and
exercise program (not specified).2 weeks daily treatment,
Monday-Friday (10 sessions),
with 30 mins MLD and ban-
dages applied and left in
place until next scheduled
treatment.
Followed by 6 months daily
self-care (maintenance phase)
Exercises performed 10–15
minutes once per day during
CDT and twice per day in
maintenance phase.Qualified phy-
siotherapistsGradalski
et al. 201582Y 505
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nameBI Database of SyComponents of interventionstematic Reviews and Implementation Reports CO
WOLTERS KLUWER HEALTH, INC.Duration and frequency
of interventionPYRIGHT  2018 THE AUTH
ON BEHALF OF THE JOANNDelivered byORS. PUBLISHED B
A BRIGGS INSTITUTStudy/
citationComplex Decon-
gestive Therapy
(CDT) continuedCDT phase I: MLD using Vodder method; multi-layer
short-stretch bandages (short-stretch bandage product speci-
fied, but no mention of other layers); remedial exercise (not
specified); skin care.10–15 sessions’ daily treat-
ment, 5 days per week. 45
mins MLD per sessionNot stated Haghighat
et al. 201375 zCDT phase I: MLD (method not specified), multi-layer low
stretch compression bandaging, remedial exercises (not
specified), skin care.
CDT phase II: ready-made compression garments (not
specified) for daytime wear, self-massage/self-MLD, reme-
dial exercises (not specified), skin care. Also taught self-
bandaging for night-time use2 weeks daily treatment, 5
times per week, with 1 hour
MLD followed by bandaging
at each session.
Then daily self-treatment
plus 3 times per week night-
time self-bandaging.Phase I: 2 certi-
fied skilled physi-
cal therapists
Phase II: patientHwang et al.
201379 §Complex Decon-
gestive Physio-
therapy (CDPT)MLD (method not specified), compression therapy (not
specified), remedial exercises with breathing exercises
(listed)2 weeks daily treatment, 5
times per week (10 sessions).
Treatment time for MLD not
specified. Then 6 weeks daily
self-administered CDPT.Physical therapist
Self-administered
CDPT by patientKim et al.
201080CDPT þ Active
Resistive ExerciseMLD (method not specified), compression therapy (not
specified), remedial exercises (specified) with breathing
exercises, plus Active Resistive Exercise (ARE) program
(specified) using 0.5 kg dumbbell while wearing compression
garment (not specified) or multi-layer compression bandage
(not specified).
Subsequent maintenance phase of self-administered
CDPTþARE using 1 kg dumb-bell (if tolerated).2 weeks daily treatment, 5
times per week (10 sessions),
with 15mins ARE. Treat-
ment time for MLD not
specified. Then 6 weeks self-
administered CDPTþARE.Physical therapist
Self-administered
CDPT by patientKim et al.
201080Low level laser
therapy (LLLT)Laser diode (product specified), output power 10 Watts at
890nm wavelength. Treatment to five points in axilla at
1 cm distance from skin, energy density 1.5J/cm23 weeks of treatment, 3
times per week (treatment
session time not specified),
then 8 week break followed
by 3 more weeks treatment
as before. Total 18 sessions.Not stated Kaviani et al.
200681Sham laser Sham irradiation reported to be under strictly controlled
double-blinded conditions – sham conditions not specified3 weeks of sham treatment,
3 times per week (session
time not specified), then 8
week break followed by 3
more weeks sham treatment
as before. Total 18 sessions.Not stated Kaviani et al.
200681zprospective before and after (uncontrolled) study.
§retrospective case review (uncontrolled) study.Y 506
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